Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: The role of CXCL cytokines

Oncogene

Volumn 31, Issue 13, 2012, Pages 1683-1694

  Grepin, R ^a   Guyot, M ^a   Jacquin, M ^a   Durivault, J ^a   Chamorey, E ^b   Sudaka, A ^b   Serdjebi, C ^c   Lacarelle, B ^c   Scoazec, J Y ^d   Negrier, S ^e   Simonnet, H ^f   Pages, G ^a  

^a CNRS   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSERM   (France)

^e CENTRE LÉON BÉRARD   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

angiogenesis; bevacizumab; CXCL cytokines; EGF

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; MAB 208; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BB; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER SPECIFIC SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPH VESSEL; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR CELL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKIN-8; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS; MUS MUSCULUS;

EID: 84859423059     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.360     Document Type: Article

References (37)

1. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G et al. (2004). Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101: 11791-11796. (Pubitemid 39095373)
2. Bieche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L et al. (2007). CXC chemokines located in the 4q21 region are upregulated in breast cancer. Endocr Relat Cancer 14: 1039-1052. (Pubitemid 351252435)
3. Cao Y, Wang L, Nandy D, Zhang Y, Basu A, Radisky D et al. (2008). Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res 68: 8667-8672.
4. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB et al. (2011). Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121: 1313-1328.
5. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A et al. (2008). Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 111: 1201-1207. (Pubitemid 351213401)
6. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S et al. (2009). Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10: 247-257.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
8. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S et al. (2010). Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144-2150.
9. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111. (Pubitemid 350296300)
10. Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G. (2007). Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol Biol Cell 18: 4648-4658. (Pubitemid 350060189)
11. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E et al. (2004). The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332. (Pubitemid 38418804)
12. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M et al. (2010). CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120: 485-497.
13. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. (2007a). Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 25: 1747-1752. (Pubitemid 46797956)
14. Hainsworth JD, Spigel DR, Sosman JA, Burris 3rd HA, Farley C, Cucullu H et al. (2007b). Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin Genitourin Cancer 5: 427-432. (Pubitemid 351219695)
15. Harper SJ, Bates DO. (2008). VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8: 880-887.
16. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN et al. (2010). Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063-1071.
17. Jain RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
18. Joyce JA, Pollard JW. (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
19. Kerbel RS. (2008). Tumor angiogenesis. N Engl JMed 358: 2039-2049.
20. Kim JY, Song HJ, Lim HJ, Shin MG, Kim JS, Kim HJ et al. (2008). Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission. Mol Cell Proteomics 7: 431-441. (Pubitemid 351298454)
21. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY et al. (2010). Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28: 453-459.
22. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M et al. (2009). M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 206: 1089-1102.
23. Levashova ZB, Sharma N, Timofeeva OA, Dome JS, Perantoni AO. (2007). ELR+-CXC chemokines and their receptors in early metanephric development. J Am Soc Nephrol 18: 2359-2370. (Pubitemid 47208110)
24. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC et al. (2010). Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28: 3491-3497.
25. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY et al. (2008). Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100: 359-372. (Pubitemid 351480526)
26. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. (2005). The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 175: 5351-5357. (Pubitemid 41456421)
27. Milanini J, Vinals F, Pouysségur J, Pagès G. (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273: 18165-18172. (Pubitemid 28334735)
28. Oliver G, Srinivasan RS. (2010). Endothelial cell plasticity: how to become and remain a lymphatic endothelial cell. Development 137: 363-372.
29. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
30. Pillai MM, Iwata M, Awaya N, Graf L, Torok-Storb B. (2006). Monocyte-derived CXCL7 peptides in the marrow microenvironment. Blood 107: 3520-3526.
31. Quatrale AE, Porcelli L, Silvestris N, Colucci G, Angelo A, Azzariti A. (2011). EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci 16: 1962-1972.
32. Sparmann A, Bar-Sagi D. (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447-458. (Pubitemid 39469981)
33. Vandercappellen J, Van Damme J, Struyf S. (2008). The role of CXC chemokines and their receptors in cancer. Cancer Lett 267: 226-244.
34. Xie K. (2001). Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391.
35. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY et al. (2009). Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69: 7905-7910.
36. Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ. (2005). Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J Biol Chem 280: 42694-42700. (Pubitemid 43049228)
37. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434. (Pubitemid 36910021)